MolDX: EndoPredict Breast Cancer Gene Expression Test

This contractor provides limited coverage of the EndoPredict assay for post‑menopausal women with early‑stage (T1‑T3, N0‑N1) ER‑positive, HER2‑negative breast cancer, including node‑negative patients and those with 1–3 positive nodes, when adjuvant endocrine therapy is being considered. The test is intended to identify patients with low 10‑year distant recurrence risk who may safely forgo chemotherapy. Coverage is restricted to the specified clinical population and requires documentation of menopausal status, TNM stage, node status, ER/HER2 results, and the clinical intent to consider endocrine therapy in lieu of chemotherapy.

"Post‑menopausal women diagnosed with early‑stage breast cancer (TNM stage T1‑T3, N0‑N1) who are ER‑positive and HER2‑negative are eligible for the EndoPredict test."

Sign up to see full coverage criteria, indications, and limitations.